Lorlatinib and Amivantamab: A Paradigm Shift in &lt;i&gt;EGFR&lt;/i&gt; and &lt;i&gt;ALK&lt;/i&gt; Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making. This evidence concerns the gene ALK and non-small cell lung carcinoma.